A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Trial Profile

A Randomized, Open-Label Study Comparing the Combination of YONDELIS and DOXIL/CAELYX With DOXIL/CAELYX Monotherapy for the Treatment of Advanced-Relapsed Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancer

Recruiting
Phase of Trial: Phase III

Latest Information Update: 27 Aug 2017

At a glance

  • Drugs Trabectedin (Primary) ; Dexamethasone; Doxorubicin liposomal
  • Indications Fallopian tube cancer; Ovarian cancer; Peritoneal cancer
  • Focus Registrational; Therapeutic Use
  • Sponsors Janssen; Janssen Research & Development; Janssen-Cilag
  • Most Recent Events

    • 20 Jan 2017 Planned End Date changed from 1 Jun 2019 to 1 Dec 2019.
    • 22 Dec 2016 Planned End Date changed from 1 Sep 2018 to 1 Jun 2019.
    • 25 Nov 2015 Planned End Date changed from 1 Dec 2018 to 1 Sep 2018 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top